Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2025 14:00 ET | Source: AstuteAnalytica India Pvt. Ltd.

Scaffold Technology Market is Poised to Reach Valuation of US$ 5,570.75 Million By 2033 | Astute Analytica

Chicago, March 20, 2025 (GLOBE NEWSWIRE) -- The global scaffold technology market was valued at US$ 1,395.15 million in 2024 and is anticipated to reach US$ 5,570.75 million by 2033, growing at...
March 03, 2025 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today...
February 28, 2025 10:00 ET | Source: SNS Insider pvt ltd

Digital Camera Market to Reach USD 12.45 Billion by 2032 | SNS Insider

Pune, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Digital Camera Market Size Analysis: “The Digital Camera Market was valued at USD 8.04 billion in 2023 and is projected to reach USD 12.45 billion by 2032,...
February 27, 2025 10:00 ET | Source: SNS Insider pvt ltd

Data Analytics Market Size to Surpass USD 483.41 Billion by 2032 Owing to Rising Adoption of AI & Machine Learning Technologies

Pune, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Data Analytics Market Size Analysis: “The Data Analytics Market size was USD 52.68 Billion in 2023 and is expected to reach USD 483.41 Billion by 2032,...
February 27, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

PURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the “Company” or...
February 26, 2025 07:00 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

Masked Analysis Shows Participants Receiving Oral Zervimesine for at Least 6 Months Experienced Slower Lesion Growth than Participants Receiving Placebo Following the Futility Analysis, Management...
February 25, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

PITTSBURGH, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative...
February 20, 2025 09:30 ET | Source: SNS Insider pvt ltd

Micro Motor Market Size to Exceed USD 81.37 Billion by 2032, at 7.30% CAGR | SNS Insider

Austin, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Micro Motor Market Size & Growth Insights: According to the SNS Insider, “The Micro Motor Market was valued at USD 43.30 billion in 2023 and is...
February 20, 2025 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

- Chemical process enhances room temperature stability - - Provisional patent applications filed - PURCHASE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company”...
February 19, 2025 10:00 ET | Source: Theia Analytics Group, Inc.

THEIA Analytics Group Appoints Greg Wallig Chief Strategy Officer to Lead Commercialization of Revolutionary Corporate Governance Solution

WASHINGTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- THEIA Analytics Group, Inc, which provides real-time, actionable governance and risk insights, named Greg Wallig the new Chief Strategy Officer of the...